Biotech recruitment: a global challenge

27 July 2018

Strictly speaking, the modern biotech industry can be dated to the discovery of penicillin, first synthesized by Alexander Fleming in 1928.

However, it’s not until the 1980s that technologies such as DNA editing started to mature, creating a range of sophisticated and transformative therapeutic techniques - and a race to secure funding, technologies and expertise.

This decade saw a boom in the development of therapies such as human growth hormone, interferon and recombinant insulin, all synthesized in the lab and commercialized at scale. Firms like Biogen (Nasdaq: BIIB), Amgen (Nasdaq: AMGN) and Genentech created an industry from scratch on the back of entirely original medical research.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK